NURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time?

Similar documents
TELEPHONE SCREENING DEMOGRAPHIC INFO

NURSING FOLLOW-UP: NALTREXONE NALTREXONE NURSING FOLLOW-UP VISIT

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

CONSENT FOR TREATMENT WITH NALTREXONE

METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

CMBHS Clinical Management of Behavioral Health Services

APPLICATION FOR Page 1/8 RESIDENTIAL TREATMENT

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Building capacity for a CHC response to Ontario's Opioid Crisis

Patient Initiation: Buprenorphine/Naloxone

Take Home Naloxone elearning Module Script

Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Buprenorphine & Controlled Substance Treatment Agreement

PSYCHIATRIC INTAKE AND TREATMENT PLAN-PART I TO BE FILLED BY PATIENT PLEASE PRINT

Tuscarawas County Health Department. Vivitrol Treatment Consent

REFERRAL FORM FOR ADMISSION TO HOMEWOOD HEALTH CENTRE

Medication Assisted Treatment

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medication-Assisted Treatment (MAT) Overview

Vivitrol Drug Court and Medication Assisted Treatment

Understanding Medication in Addiction Treatment for Drug Court Participants

Opioid Use in Youth. Amy Yule M.D. March 2,

Psychiatric Evaluation Intake Form

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Birth Control Options Chart

Click to edit Master title style. Unintended Pregnancy: Prevalence. Unintended Pregnancy: Risk Groups. Unintended Pregnancy: Consequences 9/23/2015

Talking with your doctor

Psychiatric Evaluation Intake Form

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

Opioid Dependence and Buprenorphine Management

Top of the World Ranch Treatment Centre Admissions Information Record Demographics

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

Triage, Assessment and Treatment Planning

Vermont Hub and Spoke Model Treatment Need Questionnaire

2017 Preventive Health Care Guidelines Free preventive care to help you be your healthiest.

Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant

Opioid Withdrawal, Opioid Substitution, and HIV Infection

2017 Preventive Health Care Guidelines Free preventive care to help you be your healthiest.

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

The Latest Prescription Trends for Controlled Prescription Drugs

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

Clinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.

Richard Senysyzn, MD Psychiatry for Adults 1260 River Acres Drive New Braunfels, TX , Fax. (888)

A COLLABORATIVE CARE APPROACH

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Birth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender,

Patient Information: Date: Last Name: Street Address: City: SS #: First Name: Sex: M F Birthdate: Contact Information:

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

2017 Preventive Health Care Guidelines

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff May 15, 2017)

John Murphy DO, MS Lynx Healthcare

Female New Patient Questionnaire

Treatment Approaches for Drug Addiction

GOALS AND OBJECTIVES

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Prescription Opioid Addiction

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

Vivitrol Vs. Suboxone

Evergreen Behavioral Health Psychiatric Intake Form. Name: Date: Date of Birth:!

Buprenorphine addiction

Child and Youth Background Information

ALLERGIES 8. Have you ever had any allergic reaction (bad effect) to a medicine or shot?

Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Proposed Revision to Med (i)

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2017)

Vivitrol/Suboxone. Comparison Study Summary

Methadone and Pregnancy

Reduce hunger and help control cravings with CONTRAVE

National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

REFERRAL SOURCE GUIDELINES. Listed below is a general outline of the referral, interview and intake process at Last Door Recovery Centre.

Intake Form. Presenting Problems and Concerns. When did it start and how does it affect you:

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction

Barriers to recovery for Buprenorphine Patients in Bangor, Maine

Protocol For: Personally Furnishing Naloxone. Update Log

Prescription Opioids

Top of the World Ranch Treatment Centre Admissions Information Record Demographics

ALLERGIES. If yes, please list the food and non-medication (i.e. latex) allergies and type of reaction you had: MEDICATIONS

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

HEALTHWEST. Procedure. No Prepared by: Effective Date: June 1, 2017 Revised Date: November 13, 2018 Cyndi Blair, RNBC Chief Clinical Officer

Addiction and Recovery Treatment Services (ARTS) Reimbursement Structure

VASECTOMY INFORMATION AND CONSENT

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Methadone and Naltrexone ER

Adult Health History Form Preferred Name: 1

Medical Assisted Treatment of Opioid

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

Welcome to the Opioid Overdose Prevention Project

Transcription:

NURSING INTAKE Provider Name: Provider Signature: Date: Nursing Summary Are you pregnant at this time? 3 = Don t know 4 = Tubal ligation 5 = Menopause 6 = History of hysterectomy 7 = Other: 8 = N/A patient is male If no, are you on birth control? If yes, which method of contraception are you currently utilizing? (check all that apply) 1 = Relying on male condoms 2 = Oral contraceptives 3 = Injection (e.g., Depo-Provera) 4 = Hormonal implant 5 = Intrauterine device/contraception (IUD or IUC) 6 = Vaginal ring 7 = Patch 8 = Female barrier method (e.g., diaphragm, female condom) 9 = Rhythm/Fertility Awareness Methods/Withdrawal 10 = Other: 1 of 9

SUBSTANCE USE HISTORY What is your substance of choice? Opioid: Heroin Fentanyl Oxycodone product Buprenorphine Methadone Other opioid Benzodiazepines Age of initiation 0 If never used Date of most recent use 1 = 12 or more months ago (specify date) 2 = 3 11 months ago 3 = 1 2 months ago 4 = 1 3 weeks ago 5 = used this week Frequency 1 = less than 1 per month 2 = 1 3 times per month 3 = 1 2 times per week 4 = 3 6 times per week 5 = daily Route of administration 1 = oral 2 = smoking 3 = intranasal 4 = intravenous injection 5 = skin popping 6 = other Amounts used Alcohol Cocaine Amphetamines, including methamphetamine Tobacco/nicotine Other What substances are you currently using at this time? Include age of first use, last use, route, frequency, and quantity. 1 = Heroin 2 = Fentanyl 3 = Buprenorphine/naloxone 4 = Methadone 5 = Oxycodone product 6 = Other opioid: 7 = Cocaine 8 = Benzodiazepines 9 = Tobacco/nicotine 10 = Alcohol 11 = Amphetamines 12 = Other: 13 = Nothing 2 of 9

Have you ever overdosed? Number of lifetime overdoses: Have you ever been hospitalized due to an overdose? Was naloxone administered? How many times have you overdosed in the past year? Was your most recent overdose an attempt to kill yourself? Do you have any history of any other addictive behaviors such as? 1 = Gambling 2 = Sex 3 = Shopping 4 = Eating disorder (overeating, bulimia, anorexia) 5 = Other 6 = No Comments: 3 of 9

Methadone: PRIOR SUBSTANCE USE DISORDER TREATMENT HISTORY Have you ever been on Methadone Maintenance? When and where were you on Methadone Maintenance? What was your dose? Why did you stop Methadone treatment? Are you currently on Methadone Maintenance? What is your dose? Where are you receiving services for your Methadone treatment? What is the name of your counselor at your Methadone clinic? Buprenorphine/naloxone: Have you ever been prescribed buprenorphine/naloxone (Suboxone, Zubsolv, etc.) before? If yes, when were you on buprenorphine/naloxone? What was your dose? Why did you stop taking buprenorphine/naloxone? 4 of 9

Are you still on buprenorphine/naloxone? If yes, where/who is prescribing your buprenorphine/naloxone? What was your dose? When did you receive your most recent prescription? Naltrexone: Have you ever been prescribed naltrexone (Revia, Depade, Vivitrol) before? If yes, when were you on naltrexone? Have you ever received an extended-release naltrexone injection? If yes, when was your most recent injection? Why did you stop naltrexone treatment? MENTAL HEALTH HISTORY Have you ever been diagnosed with any of the following mental health conditions? 1 = Depression 2 = Anxiety 3 = Bipolar 4 = Schizophrenia 5 = Obsessive-Compulsive Disorder (OCD) 6 = Post-Traumatic Stress Disorder (PTSD) 7 = Attention-Deficit Disorder 8 = Panic Attacks 9 = Other: Are you currently taking any medication for this/these problem(s)? If yes, what medications are you taking? 5 of 9

HEALTH STATUS Have you ever been diagnosed with any medical conditions? Mark all that apply. 1 = Diabetes (specify type): 2 = Heart disease (specify type): 3 = Cancer (specify type): 4 = Asthma 5 = Tuberculosis (TB) 6 = Endocarditis 7 = Skin infection 8 = HIV If yes, are you currently in care? 9 = Hepatitis A 10 = Hepatitis B If yes, have you been treated? 11 = Hepatitis C If yes, have you been treated? 12 = Seizure disorder Are you on medications? 13 = Head Trauma/Brain Injury 14 = Pancreatic Problems 15 = Anoxic brain injury from overdose 16 = Other (specify type): 17 = None PMH History Current Medications Allergies 6 of 9

Have you ever been tested for HIV? If yes, what was the result of your most recent test? 1 = Positive 2 = Negative 3 = Don t Know If yes, what was the date of your most recent test? Have you been tested for Hepatitis C? If yes, what was the result of your most recent test? 1 = Positive 2 = Negative 3 = Don t Know If yes, what was the date of your most recent test? Do you have any pending surgeries? Do you have chronic pain? If yes, please explain: PAIN 7 of 9

Please rate your pain, on a scale from 0 to 10, WITHOUT any pain medications (by medications we mean any medications prescribed to you in addition to any medications not prescribed to you) 0 1 2 3 4 5 6 7 Can you tell me what your goals are for treatment? 8 9 10 8 of 9

Check all appropriate boxes: OBAT program reviewed with patient, including requirements to keep medical and OBAT appointments, urine toxicology screens, and possible random call-backs with medication counts. Patient is aware of their responsibility for their buprenorphine/naloxone medication. Patient was informed to keep medication in a safe undisclosed place, out of reach of children and visitors, and in a locked storage unit. OBAT consent and contract was read to and reviewed with the patient. Patient voluntarily signed and dated consent. A copy was given to the patient and the original was placed in the chart. Opportunity for questions was provided. Discussed buprenorphine/naloxone, reviewed medication, safe administration, storage, and potential side effects, including elevations in transaminases, potential lethal interaction with benzodiazepines and ETOH. Written information also was provided to patient. Patient verbalized understanding of information provided and wished to schedule induction phase time and date. Discussed naltrexone reviewed potential side effects and adverse reactions, including injection site reactions, allergy, pneumonia, increased transaminases, depression, dizziness, opioid-blocking effects, and decreased opioid tolerance. Patients need to be opioid free for an extended period of time prior to administration to prevent precipitated or spontaneous withdrawal. Patients who are naltrexone-naive will begin with the tablet form of the medication to assess for side effects or adverse reactions. Written info was provided to patient. Patient verbalized understanding and wished to initiate naltrexone treatment. Contact numbers of medical providers and wallet-sized buprenorphine/naloxone information cards were given to patient. Patient was instructed to give these cards to family members or friends in case patient is ever hospitalized. Contact numbers of medical providers and wallet-sized naltrexone information cards were given to patient. Patient was instructed to give these cards to family members or friends in case patient is ever hospitalized. Patient also was provided with naltrexone medical identification: bracelet and/or dog tag. Patient has been informed that both buprenorphine/naloxone and naltrexone are Category C medications. Breastfeeding is a currently contraindicated during naltrexone treatment. Labs sent: complete blood count (CBC), Hepatitis A, B, and C serologies, comprehensive metabolic panel, HIV, human chorionic gonadotropin (hcg), urine toxicology screen. Overdose education was provided. Patient has been trained to use and has access to a naloxone rescue kit. After completion, scan form into patient record and provide a copy to the patient. This document has been reproduced with permission from Boston Medical Center and is excerpted from: LaBelle, C. T.; Bergeron, L. P.; Wason, K.W.; and Ventura, A. S. Policy and Procedure Manual of the Office Based Addiction Treatment Program for the use of Buprenorphine and Naltrexone Formulations in the Treatment of Substance Use Disorders. Unpublished treatment manual, Boston Medical Center, 2016. This manual or any documents therein are not a substitute for informed medical decision making by an appropriate, licensed provider 9 of 9